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Abstract
Background: The epidermal specific ablation of Trp53 gene leads to the spontaneous development of aggressive 
tumors in mice through a process that is accelerated by the simultaneous ablation of Rb gene. Since alterations of p53-
dependent pathway are common hallmarks of aggressive, poor prognostic human cancers, these mouse models can 
recapitulate the molecular features of some of these human malignancies.
Results: To evaluate this possibility, gene expression microarray analysis was performed in mouse samples. The mouse 
tumors display increased expression of cell cycle and chromosomal instability associated genes. Remarkably, they are 
also enriched in human embryonic stem cell gene signatures, a characteristic feature of human aggressive tumors. 
Using cross-species comparison and meta-analytical approaches, we also observed that spontaneous mouse tumors 
display robust similarities with gene expression profiles of human tumors bearing mutated TP53, or displaying poor 
prognostic outcome, from multiple body tissues. We have obtained a 20-gene signature whose genes are 
overexpressed in mouse tumors and can identify human tumors with poor outcome from breast cancer, astrocytoma 
and multiple myeloma. This signature was consistently overexpressed in additional mouse tumors using microarray 
analysis. Two of the genes of this signature, AURKA and UBE2C, were validated in human breast and cervical cancer as 
potential biomarkers of malignancy.
Conclusions: Our analyses demonstrate that these mouse models are promising preclinical tools aimed to search for 
malignancy biomarkers and to test targeted therapies of prospective use in human aggressive tumors and/or with p53 
mutation or inactivation.
Introduction
Mouse models of human cancer have become essential
tools for preclinical analysis of antitumoral drug discov-
ery. To demonstrate that these models faithfully recapitu-
late human disease, a deep characterization of the tumors
is required. Functional comparative genomics is one of
the most powerful techniques for such validation. More-
over, such analyses have also evidenced that mouse mod-
els display the complexity of human cancer genomes.
Cross-species studies using genomic-based technologies
have indicated the preservation of oncogene transcrip-
tional signatures [1,2] or the synteny of tumor-associated
copy number alterations [3-5]. Furthermore, comparison
between mouse and human samples have demonstrated
the conservation of somatic signature mutational events
[4,5], and have enabled the efficient identification of new
oncogenes in human cancers [6].
The p53 protein is a transcription factor that responds
to diverse stress signals (including DNA damage, onco-
gene activation and various metabolic limitations) to reg-
ulate many target genes that induce cell-cycle arrest,
apoptosis, senescence, autophagy, DNA repair and/or
metabolic changes [7,8]. As a consequence, the p53 path-
way is a crucial mechanism for effective tumor suppres-
sion. Somatic or germline mutations in TP53 gene that
compromise its function occur in around 50% of all
human cancers (IARC TP53 mutation database, version
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R14, November 2009 is the latest, [9]), and even those
tumors that retain wild-type p53 frequently show defects
in the pathways leading to its functional inactivation [10],
such as amplification of MDM2 [11]. Furthermore,
somatic mutations in TP53 have been associated with
poor outcome in most human cancers [9,11]. Impor-
tantly, both somatic and germline TP53 mutations are
usually followed by loss of heterozygosity (LOH) during
tumor progression [12], which suggest that a selective
force inactivates the remaining wild-type allele. The
majority of TP53 mutations are missense (73.6%), and
many of these missense mutant p53 forms not only lose
their tumor suppressive function and acquire dominant-
negative activities, but also gain new oncogenic proper-
ties that are independent of wild-type p53, the so called
gain-of-function mutants [12]. However, an important
proportion of mutations would give rise to a truncated
p53 protein, such as nonsense, frameshift and large dele-
tion mutations (16.6% of all mutations). The essential role
of p53 in tumor suppression has also been demonstrated
using genetically modified mice, whereby Trp53 deletion
or missense mutations induce tumor formation in multi-
ple tissues and organs [13]. We and others have reported
that the somatic inactivation of p53 tumor suppressor in
stratified epithelia, using the Cre-LoxP system (hereafter
Trp53ΔEC), induces spontaneous development of skin
squamous cell carcinoma (SCC) [14,15]. Besides, skin
tumor development is accelerated by inactivation of both
Trp53  and  Rb  genes (hereafter RbΔEC; Trp53ΔEC) [15].
Interestingly, tumors arising in both genotypes, which
originate in close proximity to hair bulge, where the adult
epidermal stem cells reside, display high aggressive char-
acteristics including premature epithelial-mesenchymal
transition (EMT) and distant metastasis (manuscript in
preparation).
Here we have characterized the differential gene
expression patterns between tumor and normal skin tis-
sue, in order to obtain putative target genes for antitu-
moral therapies and/or for biomarker discovery. We have
observed that primary tumors from Trp53ΔEC and RbΔEC;
Trp53ΔEC show a predominant overexpression of genes
involved in cell cycle progression and mitosis regulation.
The mouse tumors also display a core transcriptional
profile similar to human embryonic stem cells, a feature
associated with increased aggressiveness of human
tumors. Cross-species studies demonstrate that the over-
expressed genes could significantly identify human can-
cers bearing p53-mutations and/or highly aggressive
behavior. Collectively, we have obtained a set of genes
with reproducible overexpression in mouse samples,
which could be used as targets for preclinical antitumor
therapies and as biomarkers of malignancy in primary
tumors.
Results
Inactivation of Trp53 in stratified epithelia leads to the
generation of spontaneous epidermal tumors with a com-
plete penetrance by one year of age [15]. The simultane-
ous inactivation of Rb1  and  Trp53  leads to earlier
appearance of the tumors and faster growth at early
stages when compared to inactivation of only Trp53
alleles. To fully characterize the molecular features of
these tumors we performed gene expression profiling
using Affymetrix microarrays using total RNA from 27
carcinomas arising in Trp53ΔEC  and RbΔEC; Trp53ΔEC
mice, and 9 normal, wild type skin samples.
Gene expression comparison of tumours arising in Trp53ΔEC 
and RbΔEC; Trp53ΔEC mouse models
In both genotypes the tumors appeared as small subcuta-
neous squamous lesions originating in or close to the hair
follicles (Fig. 1a). They exhibit a fast growth leading to
poorly differentiated squamous cell carcinomas (Fig. 1b),
which rapidly progress, lose the expression of differentia-
tion markers such as K10, K6 and K17 [15], and become
highly undifferentiated carcinomas (Fig. 1c) and in, some
cases evolve to spindle cell carcinomas (Fig. 1d), possibly
by means of a premature EMT process. Overall, at the
most advanced stage Trp53ΔEC and RbΔEC; Trp53ΔEC mice
tumors are very similar and histopathologically indistin-
guishable (Fig. 1e) [15].
In order to characterize the tumor progression and to
compare tumors with different histological grade at the
molecular level, we performed supervised analysis of dif-
ferential gene expression. This analysis showed signifi-
cant differences depending on tumor histological grade
(undifferentiated/spindle vs. poorly differentiated carci-
nomas) (Fig. 2). Enrichment analysis of Gene Ontology
Biological Processes (GOBP) terms demonstrated
increased expression of genes involved in vasculature
development, cell adhesion, and endocytosis in undiffer-
entiated/spindle carcinomas with respect to poorly dif-
ferentiated carcinomas. More specifically, we have found
overexpression of genes that mediate EMT such as Snai1,
Zeb1 or Zeb2, or genes associated with EMT such as Tgf-
brII, Dab2, Vimentin, Col6a1 and Col6a2 and Adam19.
Also, we found in undifferentiated/spindle carcinomas a
significant reduced expression of genes involved in kera-
tinocyte and/or epidermal differentiation such as Cdh1
(E-cadherin), Krt17, desmocollin 1, 2 and 3, desmoplakin,
claudin 1, 4 and 8, Lama5, plakophilin 1 and 3, or plako-
globin. Some of these genes can be repressed in EMT by
Snai1,  Zeb1  or  Zeb2  transcription factors [16]. The
results confirm that the undifferentiated/spindle carcino-
mas display molecular features of EMT tumors.
The comparative analysis of tumor appearance in
Trp53ΔEC  and RbΔEC; Trp53ΔEC  mice have revealed anGarcía-Escudero et al. Molecular Cancer 2010, 9:193
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accelerated tumor onset in RbΔEC; Trp53ΔEC indicating
the existence of cooperative functions for these tumor
suppressors in epidermis, which is in contrast with the
absence of spontaneous tumors [17] and the reduced sus-
ceptibility to chemical carcinogenesis in mice lacking epi-
dermal pRb [18]. However, at the advanced stage there
are no overt differences in differentiation, grade or
growth rate between the two genotypes [15]. In order to
identify possible molecular differences/similarities in the
tumors arising in both mouse models, we also performed
a supervised analysis of differential expression based on
mouse genotype (Trp53ΔEC  vs  RbΔEC; Trp53ΔEC). This
analysis revealed that tumors in both genotypes are very
similar, as only 83 probesets were differentially expressed
at the significance level of FDR < 0.1 (Additional file 1).
The result might indicate that although Rb somatic inac-
tivation in double deficient mice accelerated the appear-
ance and initial growth of tumors, it does not importantly
contribute to the overall gene expression pattern of overt
primary tumors.
Trp53ΔEC and RbΔEC; Trp53ΔEC mouse tumors are enriched in 
human stem cell genes
Using gene enrichment analysis of 13 partially overlap-
ping gene signatures that were compiled from the litera-
ture, Ben-Porath et al. reported that high grade,
metastatic human tumors displayed gene expression pro-
grams similar to those described for human embryonic
stem (ES) cells, and are also enriched for targets of key
regulators of ES cell identity (Oct4, Sox2, and Nanog) and
targets of Myc oncogene (key regulator of cell differentia-
tion) [19]. On the contrary, these ES-like human tumor
samples displayed down-regulation of genes bound by the
Polycomb repressive complex 2 (PRC2) [19]. Ben Porath
et al. study represents an important evidence of the simi-
larities between gene expression programs of metastatic
tumors and ES cells.
Spontaneous tumors arising in Trp53ΔEC and RbΔEC;
Trp53ΔEC mice are high grade and aggressive, they origi-
nate from hair follicles (where adult epidermal stem cells
reside) and, at early stages, display increased expression
of certain epidermal stem cell markers such as keratin
K15 [15]. Therefore, we wanted to analyze whether they
also share gene expression patterns of human ES cells. To
this, we downloaded the 13 gene signatures (described in
Materials and Methods) used by Ben-Porath et al, and
performed a similar analysis using Gene Set Enrichment
Analysis (GSEA) [20,21] on the mouse samples. We
o b s e r v e d  t h a t  t u m o r s  a r e  e n r i c h e d  i n  h u m a n  E S  c e l l
genes, and in targets of Nanog, Sox2, and Myc transcrip-
tion factors (Table 1). Conversely, mouse tumors dis-
played repression of Polycomb targets. The analysis
demonstrates similar patterns of human ES cells gene
programs within the mouse epidermal tumors from p53-
deficient mouse, thus resembling most of the molecular
features of high-grade, malignant human tumors.
Generation of a gene expression signature for epidermal 
tumors from p53-deficient mouse
Gene expression profiles comparing normal and tumoral
samples provide information about genes that could dis-
play important functions in the carcinoma maintenance
or aggressiveness, and non essential roles in the normal
tissue. The therapeutic inhibition of these genes would
not affect normal tissue homeostasis but may affect
tumor growth or metastasis, thus becoming potential
molecular targets for therapy. In addition, interspecies
comparison between human and mouse could also be
useful to determine which genes display similar expres-
sion patterns so they can be considered validated targets
for therapy and/or biomarkers of human cancer. In order
Figure 1 Histological analysis of tumors arising in Trp53ΔEC and 
RbΔEC; Trp53ΔEC mice. Histology sections showing (a) a representative 
example of subcutaneous tumor mass arising from the hair follicle in a 
RbΔEC; Trp53ΔEC mouse, (b) a poorly differentiated SCC from a RbΔEC; 
Trp53ΔEC mouse, (c) a highly undifferentiated tumor from a Trp53ΔEC 
mouse, and (d) a spindle cell carcinoma in a RbΔEC; Trp53ΔEC mouse. (e) 
Proportion of tumors arising in both mouse models. Advanced stage 
tumors were classified histopathologically into poorly differentiated, 
undifferentiated and spindle cell carcinomas.
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Figure 2 Gene expression differences of Trp53ΔEC and RbΔEC; Trp53ΔEC mouse tumors based on histological grade. Gene expression deregulation re-
lated to carcinoma differentiation was done using supervised Ttest analysis between poorly differentiated carcinomas and undifferentiated/spindle carcino-
mas. Results are shown for 2% of probesets overexpressed (n = 902, FDR corrected p-val = 0.002) or underexpressed (n = 902, FDR corrected p-val = 0.001) in 
undifferentiated/spindle carcinomas. (a) Hierarchical clustering analysis using euclidean distance and average linkage clustering of probesets and all carcino-
mas: poorly differentiated (green), undifferentiated/spindle (red), and mixed, containing differentiated and undifferentiated areas (blue). (b) Enrichment anal-
ysis in GO biological processes of the deregulated genes evidenced overexpression of genes involved in vasculature development, cell adhesion, and 
endocytosis (red bars), and underexpression of genes involved in keratinocyte differentiation or cell death (green bars) in undifferentiated/spindle carcinomas. 
p-val: significance of enrichment.
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to identify such possible genes in our mouse tumor sam-
ples, we divided the full dataset in two datasets contain-
ing 20 and 16 samples selected randomly: i) a training
dataset, with 5 normal skin and 15 tumors from both gen-
otypes, which were used to compare with human tumors
and to select gene targets/biomarkers; ii) a testing data-
set, with 4 normal skin and 12 tumors from both geno-
types, in order to validate the selected genes in new,
external samples.
Differential expression analysis between mouse tumors
and control normal skin in the training dataset provided a
gene expression signature of 682-probesets (371 overex-
pressed and 311 underexpressed in tumors) (Additional
files 2 and 3). Unsupervised hierarchical clustering analy-
sis and principal component analysis of the samples using
this gene signature revealed a high degree of similarity
between tumors of both Trp53ΔEC and RbΔEC; Trp53ΔEC
mouse genotypes (Fig. 3a and 3b), which is in line with
the above results (see Additional file 1). Thus, the
observed gene expression profile can be ascribed to a
tumor gene signature from p53-deficient mouse, as
somatic inactivation of Trp53 alleles is the common hall-
mark of both transgenic lines. Consistent with the func-
tional roles of p53, most of the overexpressed genes in the
tumors are involved in DNA replication and repair, or
genomic instability and cell cycle checkpoint, as evi-
denced by enrichment analysis of GOBP terms (Fig. 3c).
This finding is coincident with previous reports showing
that TP53 mutations are associated with increased global
genomic instability [22] and the observation of a high
chromosomal instability in tumors and in pretumoral
skin of Trp53ΔEC mice [23]. In sharp contrast, downregu-
lated genes are related to muscle development and physi-
ology , that may be explained by the absence of dermal
muscle layers in tumor samples (see also Fig. 1).
Gene expression comparison between mouse and human 
tumors
To test whether the gene expression patterns that charac-
terize Trp53ΔEC  and RbΔEC; Trp53ΔEC  mouse tumors
(training dataset) are also present in human cancers with
TP53 mutations and/or with poor clinical outcome, we
performed an exhaustive comparison of the mouse tumor
signature (682-probesets) with gene datasets of human
cancer samples using the Oncomine human cancer
genomics database (see Materials and Methods) [24,25].
First we analyzed the genes overexpressed in the mouse
tumors (371 probesets), and compared them with the
overexpressed genes in human samples bearing TP53
mutations. This meta-analysis showed a very significant
overlap with many human epithelial and non-epithelial
cancers, indicating that multiple genes overexpressed in
the mouse epidermal tumors are in common with human
tumors from distinct body sites and characterized by
bearing mutant TP53 gene (Fig. 4a and Additional file 4).
To study the existence of possible correlation with differ-
ent types of p53 mutations in human tumors, we ana-
lyzed in further detail a breast cancer dataset containing
gene expression and p53 mutation data of 247 patients
[26], and which also showed the highest overlapping sig-
Table 1: GSEA of human stem cell signatures
Gene Set Name (N)1 Number of enriched genes NES FDR q-val
ES EXP1 (315) 128 2.16 <0.0001*
ES EXP2 (32) 9 1.89 <0.0001*
MYC Targets2 (664) 182 1.63 0.0022*
SOX2 Targets (584) 166 1.54 0.0058*
MYC Targets1 (199) 55 1.47 0.013*
NANOG Targets (797) 225 1.38 0.021*
OCT4 Targets (242) 63 1.22 0.068
NOS Targets (152) 32 1.08 0.23
H3K27 BOUND (886) 245 -1.65 0.0026*
PRC2 Targets (508) 126 -1.59 0.0038*
EED Targets (800) 183 -1.55 0.0042*
SUZ12 Targets (819) 201 -1.65 0.005*
NOS TFS (32) 5 -1.08 0.24
1 N: number of genes from each gene set in mouse chip.
NES: normalized enrichment score.
NES > 0: enrichment in tumors; NES < 0: enrichment in normal skin.
*Significant enrichment.García-Escudero et al. Molecular Cancer 2010, 9:193
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Figure 3 Tumor signature of p53-deficient mouse. (a) Unsupervised hierarchical clustering of skin tumors using the tumor signature of p53-defi-
cient mouse was done with Pearson distance metrics (average linkage method), and the clustering was iterated 100 times using bootstrap resampling. 
Columns represent samples, and rows are genes. Green samples are normal control skin from adult mice. Orange samples are skin tumors from 
Trp53ΔEC genotype, and red samples from RbΔEC; Trp53ΔEC. (b) Principal Component Analysis of animal samples using the tumor signature of p53-de-
ficient mouse. Normal skin and mouse tumors are clearly separated along the principal component 1 (PC1), demonstrating that the signature clearly 
distinguishes between normal and cancer tissues. Moreover, tumors arising from either genotype (Trp53ΔEC or RbΔEC; Trp53ΔEC) cluster in the same 
area, showing that the signature is common for them. Green samples are normal skin from adult mice. Orange samples are skin tumors from Trp53ΔEC 
genotype, and red samples from RbΔEC; Trp53ΔEC. (c) Enrichment analysis in GO biological processes from the gene signature of p53-deficient mouse. 
Overexpressed genes are related with cell cycle, mitosis, or DNA repair (red bars). Downregulated genes are involved in muscle processes, probably 
due to loss of muscle tissue in aggressive tumors (green bars). p-val: significance of enrichment.
a
c
EC Trp53
EC EC Rb ; Trp53  
Normal skin
-log10(p-val)
0 1 02 03 04 0
cell cycle
mitosis
DNA replication
regulation of cell cycle
chromosome segregation
DNA repair
cytokinesis
cell cycle checkpoint
chromosome condensation
muscle system process
muscle contraction
muscle development
myoblast maturation
myoblast development
b
UP
DOWNGarcía-Escudero et al. Molecular Cancer 2010, 9:193
http://www.molecular-cancer.com/content/9/1/193
Page 7 of 18
Figure 4 Overlapping of mouse and human tumors. (a) Gene expression overlapping between mouse tumors and human samples with TP53 mu-
tations from 7 different cancer types is shown. n: total number of human tumors analyzed. Bar plots represent the significance of the overlap between 
overexpressed genes in tumors of p53-deficient mouse and genes overexpressed in human tumor samples with TP53 mutations (p-val, Fisher's exact 
test). Numbers at left represent the gene number overlap. Aside the plot is represented the color codes for each cancer tissue. Asterisk represents the 
most significant overlapping. (b) Mouse tumors as models for missense and truncating TP53 mutations. Gene expression values of the 98 genes over-
lapping between the mouse tumors and the breast cancer samples from Ivshina et al. [26] (asterisk in panel a) with TP53 mutations (overlapping score; 
mean = 0, stdv = 1) were plotted depending on the TP53 mutation status (left) or the mutation type (right). Number of tumor samples and significance 
of mean difference is shown. (c) Gene expression overlapping between mouse tumors and human samples with poor outcome from 11 different can-
cer types is shown. n: total number of human tumors analyzed. Bar plots represent the significance of the overlap between overexpressed genes in 
tumors of p53-deficient mouse and genes overexpressed in human tumor samples with poor outcome (p-val, Fisher's exact test). Numbers at left rep-
resent the gene number overlap. Aside the plot is represented the color codes for each cancer tissue.
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nificance in the human p53-mutant tumors panel (aster-
isk in Fig. 4a) (98 overlapping genes, p-val = 1.6 × 10-66).
As a measure of the status similarity with respect to
mouse tumors, we calculated an overlapping score of
each breast cancer sample (see Materials and Methods)
and represented it as a function of TP53 mutational sta-
tus. The mean differences and significance were calcu-
lated as the tumors were grouped by TP53 mutation
status (mutant or wild type) or by mutation type (mis-
sense or truncating). As expected, the differences were
highly significant between tumor samples bearing TP53
mutation or wild type (Fig. 4b, left panel), demonstrating
that the mouse tumors expression profile could distin-
guish between both types of human tumors. Further-
more, the mean values were also significantly higher in
the samples with truncating mutations when compared
with missense mutations (Fig. 4b, right panel). Overall
these analyses suggest that mouse tumors with somatic
deficiency of both p53 alleles resemble human tumors
with TP53 mutations, especially tumors that can produce
truncated p53 proteins.
Next, we extracted common genes overexpressed in the
mouse tumors and in human tumors bearing TP53 muta-
tions. We found 51 that are overexpressed in 5 out of 10
studies of human tumors analyzed, representing a mouse
and human tumor signature associated with TP53 muta-
tion (51-gene signature) (Table 2).
On the other hand, we analyzed whether the mouse
tumor gene signature can distinguish human aggressive
tumor samples (tumors from which patients died at an
early time post surgery or diagnosis) independently of the
TP53 mutational status. Again, we found a highly signifi-
cant overlap with human cancers of different origin (Fig.
4c, and Additional file 4), including carcinomas (breast,
brain, bladder, and renal), and hematological cancers
(lymphoma and myeloma). The overlapping of the tumor
signature of p53-deficient mouse with genes differentially
expressed in human aggressive tumors suggests that this
signature could be predictive of malignant progression, in
agreement with the observation that TP53 mutations
have been associated with poor prognosis in human can-
cer [9,11]. To study this, we also extracted mouse tumor
genes that display overexpression in highly metastatic
human tumors (in 14 out of 28 studies). These genes (n =
26) represent a mouse and human tumor signature asso-
ciated with poor prognosis (26-gene signature) (Table 2).
Remarkably, 20 genes (asterisks in Table 2) are common
between the 26-gene signature (associated with poor
prognosis) and the 51-gene signature (associated with
TP53 mutation), corroborating, in agreement with others
[9,11], that TP53-mutations or p53 functional inhibition
is a common hallmark of human cancer malignancy.
These 20 genes (20-gene signature) represent biomarkers
of TP53 mutant and/or aggressive tumors, and, conse-
quently, possible therapeutic targets.
It is worth mentioning that a similar analysis was also
performed using genes showing reduced expression in
m o u s e  t u m o r s  a s  c o m p a r e d  w i t h  n o r m a l  m o u s e  s k i n .
However, the number of overlapping signatures and their
significance is lower (Additional files 4 and 5).
Validation of the 20-gene signature in the mouse testing 
dataset
In order to validate the genes of the 20-gene signature as
possible cancer targets or biomarkers, it is necessary to
analyze its predictive capability to distinguish between
normal skin and tumor samples arising in new mice.
Gene expression values for the 20 genes from the testing
mouse dataset were extracted (Fig. 5a), and the predic-
tion accuracy to distinguish between normal or tumoral
condition was calculated using Support Vector Machine
(SVM) [27], Uncorrelated Shrunken Centroid Classifica-
tion (USC) [28], K-Nearest Neighbor Classification
(KNNC) [29] and Discriminant Analysis Module (DAM)
[30]. The accuracy of the classifiers is very high, and var-
ied between 87.5% (USC), 93.8% (SVM or KNNC), or
100% (DAM) (Fig. 5b). This result demonstrates that the
20-gene signature is a good predictor of carcinoma vs.
normal skin samples, so the 20 genes could be considered
good markers of Trp53ΔEC and RbΔEC; Trp53ΔEC mouse
tumors and good targets for preclinical antitumor thera-
pies.
Patient stratification using 20-gene signature
To further confirm that the 20-gene signature obtained
could be suitable for prediction analysis of human cancer
outcome, we analyzed the overall survival of human
patients depending on the expression pattern of this sig-
nature using four studies representing three different
cancer types: breast cancer, astrocytoma, and multiple
myeloma. To do this, we computed the sum of the expres-
sion values of the 20 genes (20-gene score) in each human
tumor sample, we classified the samples depending on
this score, and stratified the samples in three groups: low,
intermediate and high score (Fig. 6). The association with
survival of the resulting sample clusters was analyzed
using Kaplan-Meier curves. The results showed that
patients displaying low scores (this is, low expression val-
ues of the 20-gene signature) had a higher survival proba-
bility than those displaying intermediate or high scores
(Fig. 6a-d), which suggests that the mouse-derived signa-
ture could help to determine the prognosis of human can-
cers.
Gene expression predictive tests have been previously
developed for breast cancer with the aim to be imple-
mented in clinical use. Thus, we wanted to analyze how
the 20-gene derived patient stratification compares withGarcía-Escudero et al. Molecular Cancer 2010, 9:193
http://www.molecular-cancer.com/content/9/1/193
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Table 2: Mouse and human tumor signatures
Gene Symbol Gene Title Gene Function
Mouse and human tumor signature associated with TP53 mutation1: 51-gene signature
ACTL6A actin-like 6A chromatin remodeling, histone H4 and H2A acetylation
ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) chromatin assembly or disassembly, regulation of 
transcription
AURKA aurora kinase A mitotic cell cycle, spindle organization
BIRC5 baculoviral IAP repeat-containing 5 microtubule cytoskeleton organization, chromosome 
segregation, spindle checkpoint
BLM Bloom syndrome, RecQ helicase-like telomere maintenance, G2/M transition DNA damage 
checkpoint
BUB1 budding uninhibited by benzimidazoles 1 homolog 
(yeast)
mitotic cell cycle spindle assembly checkpoint
C21orf45 chromosome 21 open reading frame 45 mitosis
CCNA2 cyclin A2 mitotic cell cycle G2/M transition DNA damage 
checkpoint, response to estradiol and glucagon stimulus
CDC2 cell division cycle 2, G1 to S and G2 to M APC-dependent proteasomal ubiquitin-dependent 
protein catabolic process
CDC20 cell division cycle 20 homolog (S. cerevisiae) APC-dependent proteasomal ubiquitin-dependent 
protein catabolic process
CDC45L CDC45 cell division cycle 45-like (S. cerevisiae) DNA replication checkpoint, DNA replication initiation
CDC6 cell division cycle 6 homolog (S. cerevisiae) DNA replication checkpoint, traversing start control 
point of mitotic cell cycle
CDC7 cell division cycle 7 homolog (S. cerevisiae) G1/S transition of mitotic cell cycle, DNA replication
CDCA3 cell division cycle associated 3 mitosis
CDCA8 cell division cycle associated 8 mitotic metaphase, chromosome organization
CDKN3 cyclin-dependent kinase inhibitor 3 regulation of cyclin-dependent protein kinase activity, 
G1/S transition of mitotic cell cycle
CDT1 chromatin licensing and DNA replication factor 1D N A  r e p l i c a t i o n  c h e c k p o i nt, regulation of DNA 
replication initiation
CENPA centromere protein A establishment of mitotic spindle orientation, 
nucleosome assembly
CENPE centromere protein E, 312kDa mitotic chromosome movement towards spindle pole, 
mitotic metaphase plate congression, kinetochore 
assembly
CEP55 centrosomal protein 55kDa mitosis
CHEK1 CHK1 checkpoint homolog (S. pombe) DNA damage checkpoint, G2/M transition of mitotic cell 
cycle
CKS2 CDC28 protein kinase regulatory subunit 2 regulation of cyclin-dependent protein kinase activity, 
spindle organization
CTPS CTP synthase CTP biosynthetic process, response to drug
DEPDC1 DEP domain containing 1 intracellular signaling cascade, GTPase activator activity
FEN1 flap structure-specific endonuclease 1 DNA repair, UV protection
FOXM1 forkhead box M1 regulation of transcription, DNA-dependent
GMPS guanine monphosphate synthetase GMP biosynthetic process
HMMR hyaluronan-mediated motility receptor (RHAMM) receptor activity, hyaluronic acid binding
KIF2C kinesin family member 2C establishment or maintenance of microtubule 
cytoskeleton polarity, regulation of chromosome 
segregationGarcía-Escudero et al. Molecular Cancer 2010, 9:193
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KIF4A kinesin family member 4A microtubule-based movement, anterograde axon cargo 
transport
KIFC1 kinesin family member C1 mitotic sister chromatid segregation, microtubule-based 
movement
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) regulation of DNA recombination, M phase specific 
microtubule process, NLS-bearing substrate import into 
nucleus
MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) mitotic cell cycle spindle assembly checkpoint, APC-
dependent proteasomal ubiquitin-dependent protein 
catabolic process
MCM2 minichromosome maintenance complex component 2 DNA replication initiation, regulation of transcription
MCM3 minichromosome maintenance complex component 3 DNA replication initiation, regulation of transcription
MCM4 minichromosome maintenance complex component 4 DNA replication initiation, regulation of transcription
MCM5 minichromosome maintenance complex component 5 DNA replication initiation, regulation of transcription
MCM7 minichromosome maintenance complex component 7 DNA replication initiation, regulation of transcription, 
response to DNA damage stimulus
MLF1IP MLF1 interacting protein regulation of transcription, DNA-dependent
NCAPH non-SMC condensin I complex, subunit H mitotic chromosome condensation
NDC80 NDC80 homolog, kinetochore complex component (S. 
cerevisiae)
establishment of mitotic spindle orientation, attachment 
of spindle microtubules to kinetochore
PLK1 polo-like kinase 1 (Drosophila) mitotic prometaphase, positive regulation of ubiquitin-
protein ligase activity during mitotic cell cycle
PLSCR1 phospholipid scramblase 1 phospholipid scrambling, platelet activation
PRC1 protein regulator of cytokinesis 1 mitotic spindle elongation, cytokinesis
RAD54L RAD54-like (S. cerevisiae) double-strand break repair via homologous 
recombination, response to ionizing radiation
TFDP2 Transcription factor Dp-2 (E2F dimerization partner 2) regulation of transcription, DNA-dependent; cell cycle
TMEM48 transmembrane protein 48 protein and mRNA transport, nuclear pore complex 
assembly
TOP2A Topoisomerase (DNA) II alpha 170kDa DNA replication, topological change, ligation and repair, 
chromosome segregation, positive regulation of 
apoptosis
TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) mitosis
TRIP13 thyroid hormone receptor interactor 13 double-strand break repair, transcription from RNA 
polymerase II promoter
UBE2C ubiquitin-conjugating enzyme E2C spindle organization, APC-dependent proteasomal 
ubiquitin-dependent protein catabolic process
Mouse and human tumor signature associated with poor prognosis2: 26-gene sinature
AURKA* aurora kinase A mitotic cell cycle, spindle organization
AURKB aurora kinase B mitosis, protein localization to kinetochore
BIRC5* baculoviral IAP repeat-containing 5 microtubule cytoskeleton organization, chromosome 
segregation, spindle checkpoint
BUB1* budding uninhibited by benzimidazoles 1 homolog 
(yeast)
mitotic cell cycle spindle assembly checkpoint
BUB1B budding uninhibited by benzimidazoles 1 homolog beta 
(yeast)
apoptosis, mitotic cell cycle checkpoint, APC-dependent 
proteasomal ubiquitin-dependent protein catabolic 
process
CCNA2* cyclin A2 mitotic cell cycle G2/M transition DNA damage 
checkpoint, response to estradiol and glucagon stimulus
Table 2: Mouse and human tumor signatures (Continued)García-Escudero et al. Molecular Cancer 2010, 9:193
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prognostic signatures such as 70-gene [31] or 76-gene
[32,33]. Survival curves according to 70-gene (Fig. 6a) and
76-gene (Fig. 6b) for good and poor prognosis breast can-
cer patients are very similar to the curves of low and high
20-gene scores, respectively. Furthermore, survival of
patient groups using 20-gene scores displayed similar sig-
nificance p-values compared to survival of 70-gene and
76-gene prognostic groups. Interestingly, 20-gene has 4
genes in common with 70-gene (BIRC5, BUB1, CENPA,
and CKS2) and 2 genes in common with 76-gene (PLK1
and KPNA2).
Finally, we also investigated whether the genes identi-
fied could also behave as possible biomarkers for malig-
nant progression of human cancer. To this, we analyzed
the expression of two of the genes belonging to the 20-
gene signature, UBE2C and AURKA, using immunohis-
tochemistry on tissue array samples from human cervical
(n = 55) and breast cancer (n = 86). The p53 pathway in
CDC2* Cell division cycle 2, G1 to S and G2 to M APC-dependent proteasomal ubiquitin-dependent 
protein catabolic process
CDC20* cell division cycle 20 homolog (S. cerevisiae) APC-dependent proteasomal ubiquitin-dependent 
protein catabolic process
CDKN3* cyclin-dependent kinase inhibitor 3 regulation of cyclin-dependent protein kinase activity, 
G1/S transition of mitotic cell cycle
CENPA* centromere protein A establishment of mitotic spindle orientation, 
nucleosome assembly
CHEK1* CHK1 checkpoint homolog (S. pombe) DNA damage checkpoint, G2/M transition of mitotic cell 
cycle
CKS1B CDC28 protein kinase regulatory subunit 1B regulation of cyclin-dependent protein kinase activity
CKS2* CDC28 protein kinase regulatory subunit 2 regulation of cyclin-dependent protein kinase activity, 
spindle organization
H2AFZ H2A histone family, member Z nucleosome assembly
HMMR* hyaluronan-mediated motility receptor (RHAMM) receptor activity, hyaluronic acid binding
KIF11 kinesin family member 11 mitotic centrosome separation, spindle pole body 
organization
KIF2C* kinesin family member 2C establishment or maintenance of microtubule 
cytoskeleton polarity, regulation of chromosome 
segregation
KPNA2* karyopherin alpha 2 (RAG cohort 1, importin alpha 1) regulation of DNA recombination, M phase specific 
microtubule process, NLS-bearing substrate import into 
nucleus
MAD2L1* MAD2 mitotic arrest deficient-like 1 (yeast) mitotic cell cycle spindle assembly checkpoint, APC-
dependent proteasomal ubiquitin-dependent protein 
catabolic process
MCM4* minichromosome maintenance complex component 4 DNA replication initiation, regulation of transcription
NCAPH* non-SMC condensin I complex, subunit H mitotic chromosome condensation
PLK1* polo-like kinase 1 (Drosophila) mitotic prometaphase, positive regulation of ubiquitin-
protein ligase activity during mitotic cell cycle
PLK4 polo-like kinase 4 (Drosophila) positive regulation of centriole replication
TOP2A* Topoisomerase (DNA) II alpha 170kDa DNA replication, topological change, ligation and repair, 
chromosome segregation, positive regulation of 
apoptosis
TPX2* TPX2, microtubule-associated, homolog (Xenopus laevis) mitosis
UBE2C* ubiquitin-conjugating enzyme E2C spindle organization, APC-dependent proteasomal 
ubiquitin-dependent protein catabolic process
1Genes were selected if they have a significant differential expression between wild type and TP53-mutated human tumors, in at list 5 out of 
10 human studies (Fig. 4a)
2Genes were selected if they have a significant differential expression between primary tumors with poor versus good outcome in at list 14 
out of 28 human studies (Fig. 4c)
*Genes common between both lists: 20-gene signature
Table 2: Mouse and human tumor signatures (Continued)García-Escudero et al. Molecular Cancer 2010, 9:193
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Figure 5 Validation of 20-gene signature in the mouse testing dataset. (a) Hierachical clustering (pearson distance, average linkage) of the 20-
gene signature expression pattern in the testing dataset. Sample colors: green, normal control skin; red, mouse tumors. (b) Prediction analysis results. 
Shown is the real number of samples belonging to either normal skin class or tumor class, the classification result for each class using 4 different pre-
diction methods, and the accuracy of the methods.
a
b Method Normal skin Tumor Accuracy (%)
SVM 5 11 93.8
USC 6 10 87.5
KNN 5 11 93.8
DAM 4 12 100
Real class 4 12
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both cancer types is frequently inhibited, either by
expression of human papillomavirus E6 oncogene, which
induces p53 protein degradation in cervical carcinomas,
or by mutation of the TP53 gene in breast carcinomas. As
the tissue collections include primary cancer samples of
different tumor grades, we could relate the expression of
both proteins with tumor grade. Furthermore, in the case
of breast cancer, we could assess the expression in metas-
tases. The analysis of immunohistochemical data (Fig. 7)
revealed that UBE2C and AURKA expression levels are
higher in undifferentiated tumors of cervical (p < 0.0001
and p < 0.004, for UBE2C and AURKA respectively) and
breast (p < 0.001 and p < 0.0001, for UBE2C and AURKA
respectively) cancer samples. Moreover, in both cases
there is significant correlation between the expression
levels of these putative biomarkers and grade (p < 0.001
and p < 0.02, for cervix and breast tumors respectively).
As undifferentiated tumors are more aggressive and met-
astatic, we can suggest that UBE2C and AURKA are over-
expressed in malignant tumors. Furthermore, expression
levels are higher in metastases of breast cancer tumors (p
< 0.001 and p < 0.01, for UBE2C and AURKA respec-
tively), which again points to a role for these proteins in
metastatic behavior.
Collectively, these results demonstrate that the mouse
tumor derived 20-gene signature efficiently distinguishes
groups of patients with different outcomes and from dif-
ferent types of human cancer.
Discussion
Mouse models of human cancer could potentially be used
as tools for preclinical analysis of antitumor therapies.
However, before doing so, a full molecular characteriza-
tion of the animal tumors is necessary to be able to com-
pare them with the human tumors counterpart and to
validate them. Gene expression studies are perfectly
Figure 6 20-gene signature can identify patient tumor samples with poor outcome from different human cancer types. Three human cancer 
types were analyzed: breast cancer [31,32] (a and b), astrocytoma [51] (c) and multiple myeloma [50] (d). The probeset with maximal values was se-
lected for those genes with multiple probesets. Expression values for each gene were mean centered (mean = 0, stdv = 1), and the sum of the expre-
sion values of the 20 genes for each patient sample was computed (20-gene score, see Materials and Methods). Each dataset was divided in three 
groups of patients depending on the 20-gene score, and the survival of each group was represented in Kaplan-Meier curves. Note that the patients 
with lower scores (green color) display better survival than those with intermediate or higher scores (blue and red colors, respectively). Survival curves 
for good prognosis (orange line) and poor prognosis (grey line) breast cancer patients according to 70-gene and 76-gene prognosis profiles are 
showed (a and b, respectively). Significance of the survival differences is shown (p-val, Wilcoxon signed-rank test). On the right of each survival plot, 
there are heat maps of the corresponding datasets, and the numbers represent the number of patients in each 20-gene score group. From top to 
botton, the samples are ranked from lowest to highest 20-gene scores. From left to right, expression values of AURKA, BIRC5, BUB1, CCNA2, CDC2, 
CDC20, CDKN3, CENPA, CHEK1, CKS2, HMMR, KIF2C, KPNA2, MAD2L1, MCM4, NCAPH, PLK1, TOP2A, TPX2, and UBE2C.
20-gene: p-val=1.5x10-6
70-gene: p-val=1.7x10-6
73
73
74
Breast Cancer_NKI a
66
66
66
Breast Cancer_Desmedt
20-gene: p-val=1.5x10-2
76-gene: p-val=2.4x10-2
b
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26
26
Astrocytoma_Phillips
p-val=3.8x10-3
c Multiple myeloma_Zhan
p-val=2.4x10-2
186
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suited approaches for such validation and comparison.
Moreover, interspecies comparison could also be useful
to determine which genes display similar expression pat-
terns in human and mouse models so they can be consid-
ered targets for therapy and/or cancer biomarkers in
preclinical settings. Here we report the gene expression
profiling of mouse tumors arising in epidermis as a con-
sequence of the somatic ablation of either Trp53 or Trp53
and Rb tumor suppressor genes.
The supervised gene expression profiles of the mouse
tumors obtained demonstrated that there are no major
differences between the two genotypes. This finding is in
agreement with our previous results using different allelic
combinations and indicating that loss of Rb mediated
acceleration of tumor appearance but did not affect the
histological grade growth or aggressiveness of overt
tumors [15]. The fact that most of the overexpressed
genes are involved in cell cycle or mitotic control as well
as chromosome instability (see Fig. 3c) is also in agree-
ment with our previous data indicating that development
of tumors in the Trp53ΔEC mice is associated with early
chromosome aberrations due to deregulated centrosome
division occurring in pretumoral epidermis [23]. Under
this context, the increase in proliferation due to Rb loss
[17] can accelerate the process of tumorigenesis by
increasing the number of cells subject to such chromo-
some alterations.
Our data also suggested another important hypothesis:
since mutations in TP53 and chromosome instability are
associated with increased aggressiveness and malignancy
in human patients, we can speculate that mouse p53-defi-
cient epidermal tumors can represent a well suited model
for human malignant cancer analysis. Three major find-
ings of the mouse-to-human microarray gene expression
comparison presented here support such hypothesis: i)
there is a significant overlapping of gene expression pat-
Figure 7 UBE2C and AURKA expression in human breast and cervical carcinoma samples. Representative examples of UBE2C (a, b, e and f) and 
AURKA (c, d, g and h) expression patterns in cervical (a, b, c and d) and breast carcinoma (e, f, g and h) primary tumors of different grades. Box plots 
of relative quantitation in primary cervical (i) and breast (j) tumors of different grades and breast metastases to lymph nodes (j) are represented.
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terns between mouse tumors and human cancers bearing
mutant TP53; ii) the gene expression signatures typical of
human ES cells are displayed by mouse tumors; and iii)
the overlapping of overexpressed genes between mouse
tumors and highly malignant human primary tumors
from various origins.
The similarities that we have found between mouse
tumors and human cancer samples from different tissues
and origin could be explained by the undifferentiated sta-
tus of animal tumor samples. In this sense, the 20-gene
signature (asterisks in Table 2) shares 13 genes with a
meta-signature of undifferentiated human cancer (69
genes) previously published [34], demonstrating the
molecular similarities between mouse tumors and human
high grade samples. Furthermore, the undifferentiated
and aggressive features of the mouse tumors could be
related to the expression pattern representative of an ES
cell-like phenotype. GSEA using signatures of human ES
cell targets and key regulators of ES cell identity (Oct4,
Sox2, and Nanog) or Myc oncogene demonstrates that
mouse tumors display similar expression pattern of ES
cells.
One important feature of the spontaneous tumors aris-
ing in both genotypes is the rapid loss of the differenti-
ated phenotype. The microarray analysis corroborates
the changes observed by histology studies and confirm, at
the molecular level, that an important fraction of the
tumors undergo EMT. Since EMT also correlates with
metastatic properties, this result would also support a
highly metastatic behavior of the mouse epidermal
tumors. Analyses to characterize these features in more
detail are underway.
These observations also reinforce the possibility that
mouse models can be useful as tools for preclinical analy-
sis of potential antitumor therapies targeted against spe-
cific signaling pathways or gene products. By means of
meta-analysis approaches and interspecies comparison
we developed a signature composed by 20 genes, which
d i s p l a y s  t h e  f o l l o w i n g  a t t r i b u t e s :  i )  i t  i s  c o m p o s e d  b y
genes displaying increased expression in tumors com-
pared to normal tissue, being possible targets with impor-
tant functions in the carcinoma maintenance/
aggressiveness; ii) it is independent of the genotype
(Trp53ΔEC or RbΔEC; Trp53ΔEC) or the histological sub-
type; and more importantly, iii) it can identify human pri-
mary tumors bearing TP53 mutations and/or displaying a
more aggressive malignant behavior. In consequence, we
postulate that these 20 genes, besides of being considered
biomarkers of malignant human cancer progression,
could also be useful cancer therapeutic targets, whose
inhibition can be preclinically tested in our mouse mod-
els.
Consistent with the functional roles of p53, the 20-gene
signature contain genes involved in DNA replication and
repair, or genomic instability and cell cycle checkpoint
(Table 2). This finding is coincident with previous reports
showing that TP53 mutations are associated with
increased global genomic instability [22], and with a
report describing a signature of chromosomal instability
(CIN25) inferred from gene expression profiles that pre-
dicts clinical outcome in multiple human cancers [35].
Thus, the results suggest that chromosomal instability
mediated by the loss of TP53 could be the driving force of
metastatic behavior in primary tumors with TP53 muta-
tions.
Epidemiological studies of human cancer demonstrate
that somatic mutations in the TP53 gene are mostly mis-
sense (73.6% of all mutations). Some missense mutations
produce p53-mutant proteins that have been associated
with gain of function, or dominant-negative activities.
Supported by studies in genetically engineered mice [13],
gain of function activity renders a more transformation
prone phenotype and confers major metastatic advan-
tages. However, it is important to note that such features
have been characterized in mice when the mutations
were introduced in combination with specific oncogenes
such as K-ras [36] or in the absence of MDM2 [37]. In
addition, dominant negative of mutated p53 is only
apparent upon external carcinogenic challenges [38]. On
the other hand, an important proportion of TP53 muta-
tions found in human cancers would give rise to trun-
cated p53 proteins, such as nonsense, frameshift and
large deletion mutations (16.6% of all mutations). In this
sense, our animal models of somatic inactivation of the
Trp53 mouse gene could represent a suitable model for
these types of human mutations. Analysis of the expres-
sion deregulation similarities of the mouse tumors and
human samples with either truncating or missense TP53
mutations (Fig. 4b) suggest that animal samples share
molecular features with both types of mutations, but
more significantly with those producing truncated p53
protein. Recently, it has been described that an important
proportion of BRCA1-related human breast tumors dis-
play TP53 mutations that produce truncated p53 proteins
[39]. Approximately half of all hereditary breast cancers
are due to loss of BRCA1 or BRCA2 function. Thus, can-
cer treatments that can restore TP53 pathway function in
the mouse models could then be used to treat these
BRCA1-related breast tumors, where the p53 loss has
been suggested to be essential for tumorigenesis.
The results shown here constitute a comprehensive
metagenomic comparison of mouse p53-deficient skin
SCCs with human cancer in which we describe common
genes of p53-dependent malignancy. These genes are
markers of malignant cancer, and potential targets for
antitumor therapy. Furthermore, as these genes share
expression patterns in both species and in different types
of human cancer, our mouse models constitute validatedGarcía-Escudero et al. Molecular Cancer 2010, 9:193
http://www.molecular-cancer.com/content/9/1/193
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models to initiate preclinical analysis of antitumor thera-
pies that could be useful against p53-mutated human
cancer.
Methods
Microarray analysis of mouse skin tumors
RNA was obtained from 9 normal wild type control skin
samples and 27 tumors of both genotypes, and purified
from mice tissue as previously described [15]. Hybridiza-
tion was done to Affymetrix Mouse Gene expression
MOE430 2.0 array. Raw and processed data for training
and testing mouse datasets were deposited in the GEO
database with the accession identifiers GSE11990 and
GSE19616, respectively. Supervised analysis of differen-
tial expression between tumors with different histological
grade or arising in the two different genotypes was done
using Ttest available in the open source software Multiex-
periment Viewer 4.5 (MeV 4.5) [40]. The p-values were
corrected using FDR. To obtain a tumor signature of p53-
deficient mice, differential expression of mouse tumors
compared to normal skin tissue was performed using
Ttest and Significant Analysis of Microarrays (SAM) [41].
Probes were selected if they passed two criteria: i) Ttest
analysis with FDR corrected p-val < 3 × 10-7; and ii) SAM
analysis with q-val < 1 × 10-3 for FDR. A number of 682
probesets were selected as differentially regulated, being
371 overexpressed and 311 underexpressed in mouse
tumors (Fig. 3, Additional files 2 and 3). MOE430 2.0
Affymetrix chip probeset IDs were mapped to human
using Ailun web utility [42].
Enrichment analysis of Gene Ontology terms
Probesets identifiers of differentially expressed genes
were uploaded into DAVID Functional Annotation web
tool, which computes enrichment of Gene Ontology bio-
logical processes terms using EASE score [43,44].
Enrichment analysis in human stem cells signatures
GSEA [20,21] was used to analyze the enrichment of
human embryonic stem cell gene signatures within the
mouse tumors when compared to normal skin. Gene sets
were downloaded from Ben-Porath et al. [19], and fall
into four groups: (i) ES expressed genes: two sets of genes
overexpressed in ES cells compared to other cells and tis-
sues according to a multistudy compilation and meta-
analysis [45]; (ii) Nanog, Oct4 and Sox2 (NOS) targets:
four sets of genes whose promoters are bound and acti-
vated in human ES cells by each of these regulators of ES
cell identity, or co-activated by all three [46], and an addi-
tional set (NOS TFs) including a subset of NOS activation
targets encoding transcription regulators; (iii) Polycomb
targets: four sets representing genes bound by the Poly-
comb repressive complex 2 (PRC2) in human ES cells
[47]; and (iv) Myc targets: two sets of genes bound and
activated by c-Myc, identified in two independent studies
[48,49].
Overlapping analysis in human cancer gene expression 
studies
We used Oncomine Gene Expression Signatures database
to search for overlapping [24]. Association of the mapped
signatures with the database signatures was tested using
Fisher's exact test, and was considered significant for
Odds Ratio >1.25, and p-val < 0.01. Genes overexpressed
or underexpressed in the tumor signature of p53-defi-
cient mouse were mapped to human gene symbols and
loaded into the Oncomine database. Although both sets
of genes display similar trends, the significance was lower
for those underexpressed. We have searched for overlaps
using different filtering criteria, based on the type of
human cancer comparison performed. These criteria
were: "Molecular Subtype: Mutation" and "Clinical Out-
come". In the case of the overlapping with the Ivshina et
al. study of TP53 mutational status in breast cancer sam-
ples [26] (asterisk in Fig. 4a), as a measure of status simi-
larity with respect to mouse tumors, we calculated the
sum of the expression values of the 98 common genes in
each breast cancer sample. The higher the sum, the
greater the overlap with the mouse tumor signature.
Validation analysis in the mouse tumor testing dataset
For both the training (GSE11990) and testing mouse
datasets (GSE19616) the gene expression values for the
20-gene signature were extracted. The probeset with
maximal value was selected for genes with more than
one. Similar results were obtained using the median value
of probesets. For each method, the classifier was trained
in the GSE11990 dataset and tested in the GSE19616
dataset. Prediction methods (SVM, USC, KNNC and
DAM) were calculated using default settings within the
MeV 4.5 software.
Immunohistochemistry on human tissue arrays
FFPE tissue arrays of breast and cervical carcinomas were
purchased to Cybrdi, Inc. (Maryland, USA). Individual
clinical specimens were pathologically confirmed. Immu-
nohistochemistry was done using standard protocols on
deparaffinized sections using a polyclonal rabbit antibody
to human UBE2C or Aurora kinase A (AbCam). The
slides were microwaved for 15 min. Biotin-conjugated
secondary antibody was purchased from Jackson
Immuno-Research Laboratories and used at 1:1,000. Per-
oxidase was visualized using avidin-biotin complex
method and 3,3-diaminobenzidine kit (Vector). Double-
blind analysis was performed to assign a staining score (0
to 5) for each sample considering the intensity and the
percentage of tumor cells stained. Statistical analyses (χ2García-Escudero et al. Molecular Cancer 2010, 9:193
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and Cox correlation) were performed using SPSS soft-
ware.
External microarray datasets of human cancer
Gene expression and clinical information of human can-
cer survival curves were downloaded either from GEO
website (multiple myeloma_Zhan dataset (GSE2658) [50],
astrocytoma_Phillips dataset (GSE4271) [51], and breast
cancer_Desmedt (GSE7390) [32]), or from Rosetta
Inpharmatics website (breast cancer_NKI [31]).
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